Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics-Reference-Cited by-同舟云学术

Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics

Published:2011-04-15 Issue:8 Volume:25 Page:1361-1364
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Bacher U,Kern W,Alpermann T,Schnittger S,Kohlmann A,Klein H-U,Dugas M,Haferlach C,Haferlach T

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201180.pdf

Reference8 articles.

1. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M . Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 1997; 90: 2969–2977.

2. Harris NL, Jaffe ES, Diebold J, Flandrin G, Müller-Hermelink HK, Vardiman J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849.

3. Albitar M, Beran M, O'Brien S, Kantarjian H, Frieriech E, Keating M et al. Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia. Blood 2000; 96: 372–373.

4. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354–365.

5. Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P et al. Prognostic factors of response and overall survival in 282 higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011; 117: 403–411.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine;Hematology;2024-03-03

2. Activity of decitabine combined with all-<i>trans</i> retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER);Haematologica;2023-01-05

3. Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia;Frontiers in Oncology;2022-10-28

4. Diagnostik und Management der myelodysplastischen Syndrome*;InFo Hämatologie + Onkologie;2019-12

5. Diagnostik und Management des myelodysplastischen Syndroms;Der Onkologe;2019-10-22